Group items matching

in title, tags, annotations or url

A survey report by market research and data analytics firm, YouGov, has indicated that while there is a demand for home pharmacy delivery among consumers, the current supply or awareness of this type of service appears to be low. The poll found that approximately one-fifth of British consumers (18 per cent) have used a pharmacy delivery service in the past year. However, more than double that figure (40 per cent) expressed their intent to use such a service in the next 12 months if it were available, suggesting an opportunity for growth in this sector. This difference is especially pronounced in the Midlands, Scotland, and Wales, where the potential demand more than triples actual use. Compared to other regions, the current use of pharmacy delivery services is notably low in the Midlands, standing at 12 per cent, and in Wales and Scotland, where the collective usage rate stands at 14 per cent.

A new study by oral health brand Aquafresh has revealed how the societal pressure of having the "perfect" Hollywood smile affects children's self-esteem. The study, which included 2000 parents and children aged 4-11, found that nearly 1 in 2 British children have experienced low confidence because of how their teeth look. More than 80 per cent of children reported feeling less confident with their smile due to missing teeth (20 per cent), teeth not being "white" (20 per cent), wonky teeth (19 per cent), and gappy teeth (13 per cent). An additional 36 per cent have experienced embarrassment when smiling or laughing because of their dental appearance. The pressure for perfect teeth not only affects children but it's also a concerning issue for parents.

The Royal Pharmaceutical Society's (RPS) second roundtable on workforce wellbeing resulted in a series of collaborative actions to address pharmacy professionals' mental health and wellbeing challenges. The roundtable brought together key stakeholders from the pharmacy sector, including organisations like the General Pharmaceutical Council (GPhC), Community Pharmacy England (CPE), the National Pharmacy Association (NPA), and the profession's independent charity Pharmacist Support (PS). A report detailing the outcomes of the meeting was published on Friday, highlighting the key areas of discussion and the agreed-upon actions by the participants. During the roundtable, participants discussed the importance of understanding the workforce demographics, both nationally and locally, and using data to address wellbeing issues effectively. They also emphasised the need for using supportive standards set by the General Pharmaceutical Council (GPhC) and the Care Quality Commission (CQC) quality statement to support and empower pharmacists' wellbeing positively.

The Royal Pharmaceutical Society (RPS) on Wednesday announced that it is spearheading a new project, which aims to delve into the root causes of the growing challenge of medicines shortages across the United Kingdom and provide solutions to mitigate its impact on patients and pharmacy practice. A newly formed advisory group, chaired by RPS Fellow Dr. Bruce Warner, is set to convene later this month. The group will have experts from primary and secondary care, patient advocacy groups, the pharmaceutical industry, suppliers, regulatory bodies, governmental representatives, and NHS officials. The group aims to formulate a robust report to provide expert thought leadership and support for the wider debate on UK policy. Their work will be informed by a thorough literature review, stakeholder interviews, online RPS member events, and patient stories.

NHS England's decision to forgo commissioning puberty suppressing hormones (PSH) for children and young people, citing insufficient evidence of their safety and clinical effectiveness, follows a comprehensive review conducted by the National Institute for Health and Care Excellence (NICE) in 2020. The clinical report underscores that "PSH treatment options will not be part of routine commissioning" for people under the age of 18 in England grappling with gender incongruence or dysphoria. The NHS England review analysed nine observational studies on Gonadotrophin Releasing Hormone Analogues (GnRHa) and found no statistically significant difference in gender dysphoria, mental health, body image, and psychosocial functioning among children and adolescents treated with GnRHa. Duncan Rudkin, chief executive of the General Pharmaceutical Council (GPhC), acknowledged the challenges faced by pharmacy professionals regarding prescriptions for puberty suppressing hormones, stating:

Labour's Paulette Hamilton has raised concerns regarding the increasing reliance on pharmacy technicians in clinical practice due to staffing shortages within pharmacies. At the recent Pharmacy Inquiry session, Hamilton highlighted the mounting pressure on technicians to take on more responsibilities beyond their qualifications, attributing it to the launch of Pharmacy First in January. With almost 50,000 Pharmacy First consultations conducted in the first month alone as per a report by the Company Chemists' Association, Hamilton expressed apprehension about technicians being classified under the broad term of "pharmacy professionals," blurring the distinction between their roles and those of clinical pharmacists. She further drew parallels between this situation and the scrutiny faced by physician associates (PAs) in GP practices following a patient's death due to misdiagnosis and cautioned against technicians performing tasks beyond their expertise and urged policymakers to prevent similar incidents in pharmacy settings. Health Minister Dame Andrea Leadsom responded by defending the current approach, denying any "blurring of the edges" and emphasizing patient safety as the top priority.

British Pharma giant, GSK is planning to invest more than £200 million (about $253 million) into the United Kingdom over the next two years to strengthen its manufacturing network. The money will be used to improve the pharmaceutical group's UK sites, including construction of new facilities and assembly lines, The Daily Mail first reported on Sunday. GSK has already earmarked £67 million to upgrade its manufacturing site in Montrose, Scotland, where a new production facility is being constructed. The upgrade is expected to help boost its production of active pharmaceutical ingredients (API) for the future supply of medicines. Regis Simard, head of global supply chain, told the publication that their six UK manufacturing sites, including Montrose, are an important part of their global manufacturing network.

The UK Health Security Agency's (UKHSA) Chief Executive, Professor Dame Jenny Harries has expressed concern that measles outbreak could spread to other towns and cities unless urgent action is taken to increase Measles, Mumps and Rubella (MMR) vaccination uptake in areas at greatest risk. The virus can spread very easily among those who are unvaccinated, especially in nurseries and schools, she said on Friday (19 January) during a visit to irmingham to review the ongoing work to contain the spread of the disease. A rapid rise in cases has been seen in the West Midlands since 1 October 2023, with 216 confirmed cases and 103 probable cases recorded till 18 January. The majority of the cases (around 80 per cent) were reported from Birmingham, with about 10 per cent in Coventry, mostly affecting children aged under 10 years. Dame Jenny is calling on all local areas to increase MMR vaccine uptake rates in communities across the country.

After a year-long divestment spree, LloydsPharmacy has entered into liquidation and appointed Turpin Barker Armstrong Accountants to handle the process. In its statement of affairs report, the liquidators confirmed that the pharmacy group owes £293m to 514 creditors. This includes £228m owed to the group's former owner Admenta UK and £50m to Aurelius Crocodile - a holding company that was used to control the pharmacy business. However, creditors are set to lose out on approximately £255m as only about £8.2m can be recovered for preferential creditors and £800,000 for its unsecured creditors, the liquidators said. The healthcare chain was acquired by Aurelius when the investment firm took over its parent company, McKesson UK in 2022 for £477m.

Challenges in accessing the NHS waiting list are pushing more and more people toward private-funded alternatives for access, diagnosis and treatment, thereby increasing the demand for private health cover. According to a report published by health data provider LaingBuisson, the demand for private health cover, including medical and dental insurance and cash plans, has surged to its highest levels since 2008. The UK's overall health cover market reached £6.7 billion in 2022, an increase of £385 million from the previous year. During the period from 2020 to 2022, the market experienced annual growth rate of 6.1 per cent, a significant increase compared to the average annual growth rate of 1.7 per cent observed between 2008 and 2019, the research found. A total of 4.2 million people were subscribed to medical cover schemes in 2022. When dependents covered by these policies were included, the number reached 7.3 million - the highest count since 2008. LaingBuisson's analysis showed that medical cover volumes were steady through most of the 2010s, but began to increase alongside rises in the NHS waiting list from 2018.

As the population continues to age, the number of dementia cases in the UK could increase to rise to 1.5 million by 2040, a new study has predicted. The study report from Future Health also cautioned that over half a million people with dementia could remain undiagnosed by 2040, representing an increase of nearly a quarter of a million compared to the current figure, if there is "no progress in improving diagnosis rates." At present, approximately 850,000 individuals in the UK are living with dementia, with an estimated 315,000 cases going undiagnosed. Sponsored by Lilly, the study also highlighted significant variations in diagnosis rates across the four nations. Despite improvements, England's dementia diagnosis rate stands at 64.6 per cent, falling short of the two-thirds target.

In a recent minute of meeting, the General Pharmaceutical Council (GPhC) explored the implications of its unique authority under the Regulation of Investigatory Powers Act (RIPA), granting powers for covert surveillance. Although never utilized, the GPhC is obligated to maintain appropriate policies for such actions. During a recent meeting, the pharmacy regulator discussed that the use of RIPA be brought to a future Council workshop to discuss issues including the "ethical implications of having and using the powers, the possible use of RIPA in online pharmacy investigations and retaining the powers to deal with future scenarios as yet unknown". Led by Chief Executive and Registrar, Duncan Rudkin, the discussion underscored the importance of having robust oversight mechanisms in place. The inspection report provided assurance that the GPhC's policies align with regulatory requirements.

"We need to fix the front door to our NHS by investing in community pharmacy," asserts Daisy Cooper as more and more pharmacies "worry about the future of their business." Reflecting on the challenges faced by pharmacists during the pandemic, she emphasised their pivotal role in launching vaccination schemes across communities and the larger role pharmacies play in complementing traditional NHS facilities. Cooper recalls her collaboration with local pharmacies in St. Albans, where she worked hand in glove with them to address challenges faced by pharmacists to obtain information from NHS England regarding protocols and procedures. She told Pharmacy Business reporter that she had to work out something "hand in glove to help them get those vaccinated schemes up and running, as pharmacies were desperate to take part in the vaccination scheme" in her constituency. Describing their unique selling point (USP), Cooper emphasised the convenience and immediacy of pharmacies located in high street areas and warned that pharmacy closures "should be a real wake up call for the government."

Women who are trying to conceive should stop vaping as it may affect fertility, a study by the women's health firm Hertility has suggested. Analysis of blood samples from more than 8000 women revealed that vapers and smokers have lower levels of anti-mullerian hormone (AMH), which indicates how many eggs women have left in their ovaries. Across all age groups, AMH levels were found to be lower in people who vaped than non-vapers, suggesting that vaping could accelerate age-related decline in egg reserve. Concerningly, the report revealed that one in five British women vape while trying to get pregnant, with a significant portion also engaging in other lifestyle "vices" such as alcohol, drugs and smoking.

With scarlet fever currently circulating in England, the UK Health Security Agency (UKSHA) has urged parents to remain vigilant for potential symptoms in children. Also known as scarlatina, it is an infectious disease triggered by group A strep bacteria that can lead to symptoms such as fever, a sandpapery rash, sore throat and swollen tonsils. The latest data published by the UKHSA showed that a total of 19,528 cases of scarlet fever were reported in the 2023/24 season, of which 12,176 cases occurring between 1 January and 24 March 2024. While the number of cases recorded this year is lower than those recorded during the same period in 2023, which totaled 15,933 cases, it exceeds the average for the previous five years. "Scarlet fever is a common childhood illness, although it can affect anyone of any age," said Dr Theresa Lamagni at UKHSA. Parents are advised to contact their GP practice or NHS111 when their GP is unavailable, if they suspect they or their child are experiencing symptoms of scarlet fever.

The professional leadership body for pharmacists has urged the General Pharmaceutical Council's (GPhC) to make it mandatory to have a chief pharmacist within organisations to ensure transparency for patients, the public and pharmacy staff. On 23 January, the GPhC launched a consultation seeking views on the new draft Standards for Chief Pharmacists it has developed to strengthen pharmacy governance. These standards outlined the professional responsibilities and qualifications required by a chief pharmacist to support their organisation and its staff to deliver "safe and effective" pharmacy services. The pharmacy regulator highlighted the importance of having a registered chief pharmacist meeting these standards in hospitals (or relevant settings) to benefit from the new legislation regarding accidental errors. In response to the consultation, the RPS expressed that while meeting these standards could enhance pharmacy governance, they may not provide the framework needed to fully support staff in reporting and learning from errors.

Adding to the growing evidence of global medicine shortages, a new study has revealed that the European generic medicines market is "not in shape" to help Europe meet its public health priorities. In the past decade, the rate of generic medicines withdrawals has risen by 12 per cent, while there has been a three per cent decrease in the launch of generic products, as per Teva Pharmaceuticals' recent analysis of IQVIA data. Within the mental therapeutic area, seven per cent of generic products disappeared between 2013 and 2023, while there was a seven per cent decrease in the availability of generic cancer medicines in just six years (2017-2022). These medicines were listed on the Union List of Critical Medicines to help avoid potential shortages, as the European Commission (EC) said this could cause "significant harm to patients and pose important challenges to health systems." While mature generic products constitute the majority of the List, they remain susceptible to withdrawals, despite containing products crucial for safeguarding Europe's public health, the Teva analysis report noted. Since 2013, the number of generic products for the treatment of schizophrenia and bipolar disorder has declined by 25 per cent, with Hungary and Bulgaria experiencing the biggest loss at 83 per cent and 58 per cent respectively.

In a bid to address the ongoing deficit in staff in the UK's healthcare system, the National Health Service (NHS) has entered into a new workforce agreement with India. According to media reports, the healthcare service plans to hire 2,000 doctors from India on a fast-track basis to alleviate this pressing issue. It is learned that the NHS has set up training centres across many Indian cities such as Mumbai, Bangalore, Nagpur, Delhi, Gurugram, Indore, Mysore, Chennai, and Calicut to provide postgraduate training for the first batch of doctors. Post their training period (which ranges from six to 12 months), these doctors will be deployed at hospitals across Britain. They will also be exempted from the Professional and Linguistic Assessments Board (PLAB) examination that is otherwise mandatory for practising in the country.

All 42 integrated care boards (ICBs) in England have signed memorandums of understanding for the NHS Independent Prescribing Pathfinder programme, the first nationally-funded prescribing service in the country. Anne Joshua, interim deputy director of pharmacy commissioning at NHS England, made the revelation during the 'Chief pharmaceutical officer bi-monthly webinar' held on 7 March 2024, as reported by The Pharmaceutical Journal. In the initial phase of the programme, 210 community pharmacies across all ICBs will trial independent prescribing, ahead of establishing a commissioning framework for the service. Giving an update on the pathfinder programme, Joshua confirmed that 164 of these potential pathfinder sites had registered for the programme as of 29 February 2024. Additionally, she announced the clinical models to be followed by the participating pharmacies and presented a graph showing an overview of the services they will provide.

Many people with advanced Parkinson's disease are currently required to take more than 20 pills a day to manage their symptoms, while some necessitate treatment through a permanent feeding tube. Soon, patients will only be required to wear a portable kit to get a continuous dose of the medication delivered into their bloodstream 24 hours a day. This innovative treatment, called Produodopa, will now be made available on the NHS, providing benefit to nearly 1,000 people with advanced Parkinson's disease, according to a BBC report. James Palmer, NHS England's medical director for specialised services, told the publication that the drug's rollout will offer "a vital new option on the NHS for those who aren't suitable for other treatments such as deep brain stimulation." He added that the new therapy will help patients manage their symptoms "more effectively" and improve their quality of life.